Search

Your search keyword '"Giovanardi, Francesco"' showing total 29 results
Start Over Author "Giovanardi, Francesco"
29 results on '"Giovanardi, Francesco"'

8. New Insights in the Setting of Transplant Oncology

Author

Quaresima, Silvia, primary, Melandro, Fabio, additional, Giovanardi, Francesco, additional, Shah, Kejal, additional, De Peppo, Valerio, additional, Mennini, Gianluca, additional, Ghinolfi, Davide, additional, Limkemann, Ashley, additional, Pawlik, Timothy M., additional, and Lai, Quirino, additional

Published
2023
Full Text
View/download PDF

13. The role of hypothermic machine perfusion in selecting renal grafts with advanced histological score

Author

Ruberto, Franco, primary, Lai, Quirino, additional, Piazzolla, Mario, additional, Brisciani, Matteo, additional, Pretagostini, Renzo, additional, Garofalo, Manuela, additional, Giovanardi, Francesco, additional, Nudo, Francesco, additional, Poli, Luca, additional, Zullino, Veronica, additional, Santopietro, Pietro, additional, Rossi, Massimo, additional, Berloco, Pasquale B., additional, and Pugliese, Francesco, additional

Published
2022
Full Text
View/download PDF

14. The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis

Author

Mrzljak, Anna, Cigrovski Berković, Maja, Giovanardi, Francesco, and Quirino, Lai

Subjects
Carcinoma, Hepatocellular / drug therapy, Carcinoma, Hepatocellular / pathology, Liver Neoplasms / pathology, Diabetes Mellitus, Type 2 / complications, Humans, General Medicine, Liver Neoplasms / drug therapy, Prognosis, hepatocelular carcinoma, diabetes mellitus, NAFLD, outcomes, death, progressive disease, locoregional therapy, recurrence
Abstract

Aim: To evaluate the effect of diabetes mellitus type 2 (T2DM) on the outcomes after treatment of hepatocellular carcinoma (HCC). ----- Methods: PubMed and Cochrane Central Register of Controlled Trials Databases were systematically searched. Three HCC clinical outcomes were explored: death, progressive disease after locoregional therapies, and recurrence. Sub-analysis was performed according to the use of potentially curative (resection, transplantation, termo-ablation) or non-curative therapies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to compare the pooled data between T2DM and non-T2DM groups. ----- Results: A total of 27 studies were analyzed. Overall, 85.2% of articles were from Asia. T2MD was associated with an increased risk of death (OR 3.60; 95%CI 2.18-5.95; P

Published
2022
Full Text
View/download PDF

15. The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and metaanalysis

Author

Mrzljak, Anna, Cigrovski Berković, Maja, Giovanardi, Francesco, Quirino, Lai, Mrzljak, Anna, Cigrovski Berković, Maja, Giovanardi, Francesco, and Quirino, Lai

Abstract

Aim To evaluate the effect of diabetes mellitus type 2 (T2DM) on the outcomes after treatment of hepatocellular carcinoma (HCC). Methods PubMed and Cochrane Central Register of Controlled Trials Databases were systematically searched. Three HCC clinical outcomes were explored: death, progressive disease after locoregional therapies, and recurrence. Sub-analysis was performed according to the use of potentially curative (resection, transplantation, termo-ablation) or non-curative therapies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to compare the pooled data between T2DM and non-T2DM groups. Results A total of 27 studies were analyzed. Overall, 85.2% of articles were from Asia. T2MD was associated with an increased risk of death (OR 3.60; 95%CI 2.18-5.95; P<0.001), irrespective of the treatment approach: curative (OR 1.30 95%CI 1.09-1.54; P=0.003) or non-curative (OR 1.05; 95%CI 1.00-1.10; P=0.045), increased HCC recurrence (OR 1.30; 95%CI 1.03-1.63; P=0.03), and increased disease progressiveness (OR 1.24; 95%CI 1.09-1.41; P=0.001). Conclusions Current data provide strong evidence that T2DM unfavorably affects HCC progression and recurrence, and patients’ survival after treatment, irrespective of the approach used.

Published
2022

17. The preferential treatment of green bonds

Author

Giovanardi, Francesco, Kaldorf, Matthias, Radke, Lucas, and Wicknig, Florian

Subjects
Green Investment, ddc:330, E44, E58, Corporate Default Risk, E63, Central Bank Policy, Collateral Framework, Q58, Environmental Policy
Abstract

We study the preferential treatment of green bonds in the central bank collateral framework as an environmental policy instrument within a DSGE model with environmental and financial frictions. In the model, green and carbon-emitting conventional firms issue defaultable corporate bonds to banks that use them as collateral. The collateral premium associated to a relaxation in collateral policy induces firms to increase bond issuance, investment, leverage, and default risk. Collateral policy solves a trade-off between increasing collateral supply, adverse effects on firm risk-taking, and subsidizing green investment. Optimal collateral policy is characterized by modest preferential treatment, which increases the green investment share and reduces emissions. However, welfare gains fall well short of what can be achieved with optimal emission taxes. Moreover, due to elevated risk-taking of green firms, preferential treatment is a qualitatively imperfect substitute of Pigouvian taxation on emissions: if and only if the optimal emission tax can not be implemented, optimal collateral policy features preferential treatment of green bonds.

Published
2021

29. The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis.

Author

Mrzljak A, Cigrovski Berković M, Giovanardi F, and Lai Q

Subjects
Humans, Prognosis, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Diabetes Mellitus, Type 2 complications, Liver Neoplasms drug therapy, Liver Neoplasms pathology
Abstract

Aim: To evaluate the effect of diabetes mellitus type 2 (T2DM) on the outcomes after treatment of hepatocellular carcinoma (HCC)., Methods: PubMed and Cochrane Central Register of Controlled Trials Databases were systematically searched. Three HCC clinical outcomes were explored: death, progressive disease after locoregional therapies, and recurrence. Sub-analysis was performed according to the use of potentially curative (resection, transplantation, termo-ablation) or non-curative therapies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to compare the pooled data between T2DM and non-T2DM groups., Results: A total of 27 studies were analyzed. Overall, 85.2% of articles were from Asia. T2MD was associated with an increased risk of death (OR 3.60; 95%CI 2.18-5.95; P<0.001), irrespective of the treatment approach: curative (OR 1.30 95%CI 1.09-1.54; P=0.003) or non-curative (OR 1.05; 95%CI 1.00-1.10; P=0.045), increased HCC recurrence (OR 1.30; 95%CI 1.03-1.63; P=0.03), and increased disease progressiveness (OR 1.24; 95%CI 1.09-1.41; P=0.001)., Conclusions: Current data provide strong evidence that T2DM unfavorably affects HCC progression and recurrence, and patients' survival after treatment, irrespective of the approach used.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results